Baidu
map

Omicron BA.2几乎完全不同于新冠原始毒株

2022-03-31 Hanson临床科研 Hanson临床科研

面临这种情况,唯有及时接种疫苗。

国家卫生健康委员会31日通报,3月30日,我国内地新增新冠肺炎确诊病例1839例,新增无症状感染者6720例。

导致近2年来内地最严重新冠疫情的是新冠病毒Omicron突变株BA.2亚型

从病毒学和流行病学角度考虑,Omicron BA.2已经完全不同于早期的新冠病毒毒株。这对于所有处于疫情之中的民众而言,都是个关键信息。知己知彼,百战不殆。

从实验设计角度,我们已经认为Omicron这个病毒和其他SARS-CoV-2不是同一种病毒,因为它的病毒特性尤其决定其感染和传播能力的S蛋白特征、血清学特征及免疫逃逸、传播能力、致病性、临床表现和流行病学特征已经和2019年底开始流行的新型冠状病毒野生型完全不同了

1、新冠病毒Omicron BA.2的传播系数高达9.1

Sutter Health估计Omicron基础传播系数(R0)=7.0,因而推算出BA.2的R0高达9.1,而野生型新冠病毒R0=2.79。R0=9.1意味着在无防疫措施的情况下,一个人可以传播给9个人,结合潜伏期3天,倍增时间(doubling time)仅为2-3.3天,因此无疫情防控措施该突变株可见指数型增长。

但目前全国的增长并没有呈现指数型增长,说明在防疫措施和各种因素的作用下,病毒在内地的实际传播系数Rt很低。从这个角度来看中国的防疫措施都是奏效的。

2、Omicron有非常强的免疫逃逸

Omicron BA.1的R0就已经达到了7.0,使Omicron的传播系数达到了高传染性的腮腺炎的水平。但是腮腺炎疫苗接种可以起到持久免疫的作用,而Omicron却可以发生免疫逃逸。它和疫苗所使用的SARS-CoV-2原始野生型的血清学特征完全是截然不同的两个病毒,这是因为Omicron S蛋白上有32个突变。

所以Omicron相较于原始野生型,相当于发生了抗原漂移(antigen drift)的两种不同血清型的流感病毒。

3、从感染者临床上看,Omicron在很多国家引起的主要是无症状感染。

在南非85.3%感染是无症状感染;在疫苗接种率较高的英国其真实世界病死率已经低于流感;而两年前,SARS-CoV-2原始野生型造成的病死率是流感的34-68倍。

另外Omicron具有明显的鼻嗜性,缺乏肺嗜性

因此,这些再次印证了Omicron和SARS-CoV-2原始野生型,引起的是几乎两种不同的疾病。

原始毒株的R0=2.79,所以动态清零的公共卫生方法奏效;但随着R0上升到9.1,动态清零面临越来越大的挑战,这也是一些既往“精准防疫”有效、而现在难获成功的关键原因。

新冠病毒Alpha突变株取代了原始野生型,Delta取代了Alpha,Omicron BA.1取代了Delta,而BA.2正在取代BA.1。

Omicron BA.2的基础传播系数高达9.1,意味着极高的传染性和极大的防控难度。与此同时,疫苗接种越来越难以预防感染的同时,无症状感染者的比例也明显增高;意味着很容易发生隐匿感染。

面临这种情况,唯有及时接种疫苗。尤其是,请和家里老人确认疫苗接种信息,帮助他们及时完成加强疫苗接种。加强接种,不仅仅是帮助老年人降低发生重症的风险,也是帮助年轻人早日迎接放开日。老年人及时接种疫苗,既是维护家庭健康的基石,也是社会敢于放开的基础。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2043218, encodeId=00ed2043218da, content=<a href='/topic/show?id=d4c53e170a9' target=_blank style='color:#2F92EE;'>#原始毒株#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37170, encryptionId=d4c53e170a9, topicName=原始毒株)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Sun Dec 04 12:31:43 CST 2022, time=2022-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084716, encodeId=4dd52084e16a6, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Nov 19 08:31:43 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858026, encodeId=56421858026e4, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Sep 29 15:31:43 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208389, encodeId=fb3212083892c, content=还在坚持动态清零!, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Sun Apr 03 17:29:17 CST 2022, time=2022-04-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2043218, encodeId=00ed2043218da, content=<a href='/topic/show?id=d4c53e170a9' target=_blank style='color:#2F92EE;'>#原始毒株#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37170, encryptionId=d4c53e170a9, topicName=原始毒株)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Sun Dec 04 12:31:43 CST 2022, time=2022-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084716, encodeId=4dd52084e16a6, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Nov 19 08:31:43 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858026, encodeId=56421858026e4, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Sep 29 15:31:43 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208389, encodeId=fb3212083892c, content=还在坚持动态清零!, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Sun Apr 03 17:29:17 CST 2022, time=2022-04-03, status=1, ipAttribution=)]
    2022-11-19 xjy02
  3. [GetPortalCommentsPageByObjectIdResponse(id=2043218, encodeId=00ed2043218da, content=<a href='/topic/show?id=d4c53e170a9' target=_blank style='color:#2F92EE;'>#原始毒株#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37170, encryptionId=d4c53e170a9, topicName=原始毒株)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Sun Dec 04 12:31:43 CST 2022, time=2022-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084716, encodeId=4dd52084e16a6, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Nov 19 08:31:43 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858026, encodeId=56421858026e4, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Sep 29 15:31:43 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208389, encodeId=fb3212083892c, content=还在坚持动态清零!, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Sun Apr 03 17:29:17 CST 2022, time=2022-04-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2043218, encodeId=00ed2043218da, content=<a href='/topic/show?id=d4c53e170a9' target=_blank style='color:#2F92EE;'>#原始毒株#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37170, encryptionId=d4c53e170a9, topicName=原始毒株)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Sun Dec 04 12:31:43 CST 2022, time=2022-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084716, encodeId=4dd52084e16a6, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Nov 19 08:31:43 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858026, encodeId=56421858026e4, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Sep 29 15:31:43 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208389, encodeId=fb3212083892c, content=还在坚持动态清零!, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Sun Apr 03 17:29:17 CST 2022, time=2022-04-03, status=1, ipAttribution=)]
    2022-04-03 weigq

    还在坚持动态清零!

    0

相关资讯

Lancet:同时感染新冠和流感,重症及死亡风险大增

对超过30万名新冠住院患者的研究发现,与只感染新冠病毒相比,同时感染新冠病毒和流感病毒的成年人的重症和死亡风险会大大增加。具体来说,需要进行呼吸机治疗的风险是4.14倍,死亡风险是2.35倍。

权威比较:新冠病毒感染,感冒,流感,过敏到底有啥区别?

张文宏团队统计新冠的重症率与死亡率真的低于流感了,中国疾控中心流行病学首席专家吴尊友认为新冠肺炎不是“大号流感” ,那么新冠与流感,感冒的症状到底有什么区别呢?

英国与新冠病毒共存一个月的成绩单出来了!令人难以想象!

自2月24日起解除英格兰地区所有现行新冠限制措施,比原定计划提前了一个月。现在一个月过去了,英国成绩单如何?

国家药监局已批准20个新冠病毒抗原检测试剂

截至3月29日,国家药监局已批准20个新冠病毒抗原检测试剂产品。

Lancet Microbe:曹彬、王健伟团队发现新冠感染1年后仍有免疫记忆,抵御变体这个因素很关键

当中和抗体水平降低时,SARS-CoV-2特异性T细胞反应可能对变异株导致的严重疾病发挥重要保护作用。

Baidu
map
Baidu
map
Baidu
map